Department of Medicine, Clinical Epidemiology Division, Karolinska Institutet, Stockholm 171 77, Sweden.
Renal unit, Department of Clinical Sciences, Interventions and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Stockholm 141 52, Sweden.
J Clin Endocrinol Metab. 2022 Sep 28;107(10):e4098-e4105. doi: 10.1210/clinem/dgac456.
Kidney complications may be considerably higher in patients with chronic hypoparathyroidism (hypoPT) treated with activated vitamin D and calcium supplementation.
We aimed to investigate the risk of chronic kidney disease (CKD), urolithiasis, and hospitalization in patients with chronic hypoPT.
In this population-based cohort study in Sweden, national registries (Swedish National Patient Register, Swedish Prescribed Drug Register, and Total Population Register, 1997-2018) were used to identify patients with chronic hypoPT and controls matched by sex, age, and county of residence. We determined time to CKD and urolithiasis diagnosis, and incidence rates of hospitalization.
A total of 1562 patients with chronic hypoPT without preexisting CKD and 15 620 controls were included. The risk of developing CKD was higher in patients with chronic hypoPT compared with controls (hazard ratio [HR] 4.45; 95% CI, 3.66-5.41). In people without prior urolithiasis (n = 1810 chronic hypoPT and n = 18 100 controls), the risk of developing urolithiasis was higher in patients with chronic hypoPT (HR 3.55; 95% CI, 2.84-4.44) compared with controls. Patients with chronic hypoPT had higher incidence rates for all-cause hospitalization (49.59; 95% CI, 48.50-50.70, per 100 person-years vs 28.43; 95% CI, 28.15-28.71, respectively) and for CKD (3.46; 95% CI, 3.18-3.76, per 100 person-years vs 0.72; 95% CI, 0.68-0.77, respectively), compared with controls. Men with hypoPT appear to have a higher risk of CKD than women.
Patients with chronic hypoPT had an increased risk of CKD, urolithiasis, and hospitalization compared with controls.
接受活性维生素 D 和钙补充治疗的慢性甲状旁腺功能减退症(hypoPT)患者的肾脏并发症可能会显著增加。
我们旨在研究慢性甲状旁腺功能减退症患者发生慢性肾脏病(CKD)、尿路结石和住院的风险。
在这项瑞典基于人群的队列研究中,利用全国性登记处(瑞典国家患者登记处、瑞典处方药物登记处和全人群登记处,1997-2018 年)确定了慢性甲状旁腺功能减退症患者和按性别、年龄和居住地相匹配的对照组。我们确定了 CKD 和尿路结石诊断的时间以及住院的发生率。
共纳入 1562 例无既往 CKD 的慢性甲状旁腺功能减退症患者和 15620 例对照者。与对照组相比,慢性甲状旁腺功能减退症患者发生 CKD 的风险更高(风险比[HR] 4.45;95%CI,3.66-5.41)。在没有尿路结石既往史的人群中(n=1810 例慢性甲状旁腺功能减退症患者和 n=18100 例对照者),与对照组相比,慢性甲状旁腺功能减退症患者发生尿路结石的风险更高(HR 3.55;95%CI,2.84-4.44)。慢性甲状旁腺功能减退症患者的全因住院率(49.59;95%CI,48.50-50.70,每 100 人年)和 CKD 住院率(3.46;95%CI,3.18-3.76,每 100 人年)均高于对照组(分别为 28.43;95%CI,28.15-28.71,每 100 人年)。与女性相比,男性甲状旁腺功能减退症患者发生 CKD 的风险似乎更高。
与对照组相比,慢性甲状旁腺功能减退症患者发生 CKD、尿路结石和住院的风险增加。